Welcome to our dedicated page for Docusign SEC filings (Ticker: DOCU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning a 250-page SaaS filing to find DocuSign’s subscription growth or stock-based compensation details can derail your research day. DocuSign’s disclosures span revenue recognition rules, multi-year deferred revenue schedules, and evolving AI product lines—information that’s crucial yet hard to isolate.
Our platform fixes that. Stock Titan automatically ingests every DocuSign quarterly earnings report 10-Q filing and annual report 10-K simplified, then generates AI-powered summaries that spotlight customer count trends, remaining performance obligations, and key risk updates. Need to monitor DocuSign insider trading Form 4 transactions? Real-time alerts flag each DocuSign Form 4 insider transactions real-time, letting you track executive stock transactions Form 4 before the market reacts. When DocuSign posts an 8-K material events explained—like an acquisition or CEO change—we decode it so you don’t miss the strategic impact.
You’ll also find:
- Proxy statement sections on DocuSign proxy statement executive compensation, distilled into plain language.
- Interactive charts that turn DocuSign earnings report filing analysis into clear quarter-over-quarter visuals.
- Step-by-step guidance for understanding DocuSign SEC documents with AI, including footnote cross-links and glossary support.
DocuSign reported interim results for the quarter ended July 31, 2025, emphasizing subscription-driven revenue and continued investment in its platform. Subscriptions represented approximately 98% of revenue for the three and six months ended July 31, 2025, and the company reported $2.3 billion of transaction price allocated to remaining performance obligations, with 57% expected to be recognized within 12 months. DocuSign serves over 1.7 million customers and more than a billion users worldwide. Contract assets were $9.9 million as of July 31, 2025. Information technology costs rose, increasing $7.7 million in the three-month period and $14.5 million for the six months ended July 31, 2025, reflecting cloud migration. The company repurchased 4.9 million shares for $384.9 million during the six months and has $1.2 billion of remaining repurchase authorization. DocuSign had a credit facility of $750 million with a $250 million accordion maturing in May 2030 and reported no outstanding borrowings under it as of July 31, 2025. The filing discloses ongoing securities and derivative litigation related to prior-period statements and continued valuation allowances for certain deferred tax assets.
DocuSign director Anna Marrs received 725 restricted stock units (RSUs) on 09/04/2025, reported on a Form 4. After the grant, she beneficially owns 11,527 shares of DocuSign common stock. The RSUs carry a $0 purchase price and represent contingent rights to one share each. They vest in twelve equal quarterly installments over three years beginning June 4, 2023, conditioned on continued service, and do not expire prior to vesting.
Enrique T. Salem, a director of DocuSign, Inc. (DOCU), reported acquisitions on August 29, 2025. The filing shows Mr. Salem received 729 shares of common stock and 729 restricted stock units (RSUs) at a $0.00 price as part of an equity grant. After the transaction he beneficially owns 165,131 shares. The RSUs have a vesting commencement date of May 29, 2025 and vest in equal quarterly installments over one year, with the fourth installment subject to earlier vesting at the company’s next annual meeting or the one-year anniversary. The RSUs do not expire.
DocuSign director Anna Marrs was granted equity on 08/29/2025 consisting of 729 restricted stock units (RSUs) that convert one-for-one into common shares upon vesting. The RSUs were reported with a $0 price and have a vest commencement date of May 29, 2025, vesting in equal quarterly installments over one year, with the fourth installment accelerating to the earlier of the next annual meeting or the one-year anniversary, subject to continued service. After the reported transactions, the Form 4 shows 10,802 shares of common stock beneficially owned and 2,187 RSUs outstanding for the reporting person.
DocuSign director Teresa Briggs received a grant of 729 restricted stock units on 08/29/2025, each RSU representing the contingent right to one share of DocuSign common stock. The reported transactions show 729 RSUs acquired at a reported price of $0 and an increase in directly held common stock to 9,534 shares. Following the grant, the reporting person beneficially owns 2,187 RSUs that convert into common shares if they vest. The RSUs have a vest commencement date of May 29, 2025 and vest in equal quarterly installments over one year, with the fourth installment accelerating to the earlier of the company’s next annual meeting or the one-year anniversary, subject to continued service. The RSUs do not expire.
Mary Agnes Wilderotter, a director of DocuSign, Inc. (DOCU), received a grant of 729 restricted stock units (RSUs) on 08/29/2025. Each RSU converts to one share of common stock when vested. After the grant, the filing reports 58,345 shares beneficially owned by Ms. Wilderotter in common stock and 2,187 RSUs beneficially owned in derivative form. The RSUs have a vest commencement date of May 29, 2025 and vest in equal quarterly installments over one year, with the fourth installment potentially accelerating to the earlier of the next annual meeting or the one-year anniversary, subject to continued service. The RSUs do not expire and are either vested or canceled prior to vesting.
Director Hayes Cain A received equity awards tied to DocuSign, Inc. common stock on 08/29/2025. The filing reports an acquisition of 729 restricted stock units (RSUs) that represent the right to one share each and a separate line showing 729 shares of common stock acquired at $0. After the transactions, the reporting person is shown as beneficially owning 13,530 shares of common stock (direct) and 2,187 RSUs (derivative) following the reported transactions. The RSUs have a vest commencement date of May 29, 2025 and vest in equal quarterly installments over one year, with the fourth installment accelerating to the earlier of the next annual meeting or the one-year anniversary, subject to continued service. The RSUs do not expire.
Irving Blake, a director of DocuSign, Inc. (DOCU), reported purchases and a grant on Form 4. On 08/29/2025 Mr. Blake acquired 729 shares of common stock at no cash price (Transaction Code M), bringing his total direct beneficial ownership to 23,906 shares. He also received a grant of 729 Restricted Stock Units (RSUs) that vest quarterly over one year beginning May 29, 2025, with the final installment accelerated to the earlier of the next annual meeting or the one-year anniversary. The RSUs do not expire and convert one-for-one into common shares upon vesting. The filing was signed by an attorney-in-fact on 09/02/2025.
Form 4 filing by Peter Solvik, a director at DocuSign (DOCU), reports receipt of equity awards and current beneficial ownership. The filing shows a grant of 729 restricted stock units (RSUs) on 08/29/2025 under transaction code M, with a reported acquisition price of $0. The RSUs convert one-for-one into common shares and are reflected as 729 underlying shares held directly following the transaction.
The filing also discloses other holdings: 6,783 shares directly, 150,253 shares held by a trust, 65,558 by children’s trusts, 3 by a family partnership, and 6,458 by spouse. The RSUs have a May 29, 2025 vest commencement date and vest quarterly over one year, with specific acceleration language for the fourth installment.
FAQ
What is the current stock price of Docusign (DOCU)?
What is the market cap of Docusign (DOCU)?
